Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Softbank Grp ADR
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Recursion Pharmaceuticals
< Previous
1
2
3
Next >
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Today 4:59 EST
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
November 11, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Appoints Fred Hassan as Chair of the Board
November 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
October 26, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
October 15, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
October 15, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
August 05, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
August 04, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
July 31, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Report Second Quarter 2026 Business Updates and Financial Results on August 5th
July 29, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
June 02, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
May 29, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports First Quarter Financial Results and Provides Business Update
May 06, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Board Transition
April 30, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
April 29, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
April 07, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
March 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 25, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
February 23, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
February 18, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
February 12, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
December 01, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
November 05, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
November 05, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Participate in Upcoming Investor Conferences
November 04, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
October 28, 2025
From
Recursion Pharmaceuticals
Via
GlobeNewswire
Tickers
RXRX
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1